- Previous Close
118.00 - Open
105.00 - Bid 104.00 x --
- Ask 107.00 x --
- Day's Range
105.00 - 105.00 - 52 Week Range
59.00 - 184.00 - Volume
253 - Avg. Volume
181 - Market Cap (intraday)
10.969B - Beta (5Y Monthly) 0.48
- PE Ratio (TTM)
194.44 - EPS (TTM)
0.54 - Earnings Date Feb 12, 2025
- Forward Dividend & Yield 0.29 (0.25%)
- Ex-Dividend Date Feb 27, 2025
- 1y Target Est
--
Pro Medicus Limited, a healthcare informatics company, engages in the development and supply of healthcare imaging software, and radiology information (RIS) system software and services to hospitals, imaging centers, and health care groups in Australia, North America, and Europe. The company offers Visage RIS Visage 7 Enterprise Imaging Platform, a healthcare imaging software that provides radiologists, physicians, and clinicians with access and visualization capability for viewing 2-D, 3-D, and 4-D medical images; and picture archive and communication system (PACS)/digital imaging software. It also provides Visage RIS, a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; Promedicus.net, an e-health platform for secure email and integration products. In addition, the company offers Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. The company was incorporated in 1983 and is headquartered in Richmond, Australia.
www.promed.com.au--
Full Time Employees
June 30
Fiscal Year Ends
Sector
Industry
Recent News: PMC.F
View MorePerformance Overview: PMC.F
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PMC.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PMC.F
View MoreValuation Measures
Market Cap
12.10B
Enterprise Value
12.00B
Trailing P/E
218.72
Forward P/E
121.95
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
116.50
Price/Book (mrq)
96.57
Enterprise Value/Revenue
113.84
Enterprise Value/EBITDA
149.57
Financial Highlights
Profitability and Income Statement
Profit Margin
53.25%
Return on Assets (ttm)
32.90%
Return on Equity (ttm)
51.53%
Revenue (ttm)
184.58M
Net Income Avi to Common (ttm)
98.29M
Diluted EPS (ttm)
0.54
Balance Sheet and Cash Flow
Total Cash (mrq)
182.33M
Total Debt/Equity (mrq)
0.82%
Levered Free Cash Flow (ttm)
84.17M